Abstract
Introduction: For predicting esophagogastric varices (EGVs), the Virtual Baveno VII Consensus Workshop has proposed a combination of liver stiffness determination and platelet count measurement using a FibroScan®. However, FibroScan® is not available at all institutions. The present study aimed to develop a simple method to predict development of EGV using only general blood examination results. Materials and Methods: A total of 1,090 hepatocellular carcinoma patients were enrolled, after excluding 956 with major portal vein tumor thrombus (Vp3/Vp4) or without upper gastrointestinal endoscopy examination results available. Those with EGV (≥ grade F2) or a history of treatment for the condition were defined as positive for significant EGV, and then clinical factors were retrospectively evaluated to determine indicators of occurrence. Results: Logistic multivariate analysis showed platelet count (≤12 × 104/μL) (odds ratio [OR] 3.79, p < 0.001), mALBI grade 2a (OR 1.52, p = 0.036), and mALBI 2b or 3 (OR 3.46, p < 0.001) as significant predictive factors. Based on the OR values, platelet count (≤12 × 104/μL) and mALBI grade 2b/3 were each assigned 2 points and mALBI 2a was given 1 point, with the result termed recommendation for EGV screening (REGS) score. Significant EGV occurrence was noted in 2.9% (9/311) of the patients with a REGS score 0, 11.0% (13/118) with a score 1, 19.3% (53/274) with a score 2, 29.5% (39/132) with a score 3, and 38.0% (97/255) with a score 4 (p < 0.001). Conclusion: The findings indicate that REGS score can provide useful predictive information for development of significant EGV without the need for special equipment such as a FibroScan®.
Journal Section:
Clinical Study
References
1.
Finn
RS
, Qin
S
, Ikeda
M
, Galle
PR
, Ducreux
M
, Kim
TY
et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
. N Engl J Med
. 2020
;382
(20
):1894
–905
.2.
Llovet
JM
, Pinyol
R
, Kelley
RK
, El-Khoueiry
A
, Reeves
HL
, Wang
XW
et al. Molecular pathogenesis and systemic therapies for hepatocellular carcinoma
. Nat Cancer
. 2022
;3
(4
):386
–401
.3.
Bejjani
AC
, Finn
RS
. Hepatocellular carcinoma: pick the winner-tyrosine kinase inhibitor versus immuno-oncology agent-based combinations
. J Clin Oncol
. 2022
;40
(24
):2763
–73
.4.
Abou-Alfa
GK
, Lau
G
, Kudo
M
, Chan
SL
, Kelley
RK
, Furuse
J
et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
. NEJM Evidence
. 2022
1
8
EVIDoa2100070
.5.
Tada
F
, Hiraoka
A
, Tada
T
, Hirooka
M
, Kariyama
K
, Tani
J
et al. Efficacy and safety of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients with esophageal–gastric varices
. J Gastroenterol
. 2023
;58
(11
):1134
–1143
.6.
de Franchis
R
, Bosch
J
, Garcia-Tsao
G
, Reiberger
T
, Ripoll
C
Baveno VII Faculty
. Baveno VII; renewing consensus in portal hypertension
. J Hepatol
. 2022
;76
(4
):959
–74
.7.
Iijima
H
, Tada
T
, Kumada
T
, Kobayashi
N
, Yoshida
M
, Aoki
T
et al. Comparison of liver stiffness assessment by transient elastography and shear wave elastography using six ultrasound devices
. Hepatol Res
. 2019
;49
(6
):676
–86
.8.
Tajiri
T
, Yoshida
H
, Obara
K
, Onji
M
, Kage
M
, Kitano
S
et al. General rules for recording endoscopic findings of esophagogastric varices
. Dig Endosc
. 2010
;22
(1
):1
–9
.9.
Krige
JE
, Shaw
JM
, Bornman
PC
. The evolving role of endoscopic treatment for bleeding esophageal varices
. World J Surg
. 2005
;29
(8
):966
–73
.10.
Park
JK
, Saab
S
, Kee
ST
, Busuttil
RW
, Kim
HJ
, Durazo
F
et al. Balloon-occluded retrograde transvenous obliteration (BRTO) for treatment of gastric varices: review and meta-analysis
. Dig Dis Sci
. 2015
;60
(6
):1543
–53
.11.
The Japan Society for Portal Hypertension
Clinical manual of portal hypertension: diagnosis and treatment of esophageal and gastric varices
Tokyo
Nankodo
. 2015
. p. 50
4
.12.
European Association for the Study of Liver
. EASL clinical practical guidelines: management of alcoholic liver disease
. J Hepatol
. 2012
;57
(2
):399
–420
.13.
Mittal
S
, El-Serag
HB
. Epidemiology of hepatocellular carcinoma: consider the population
. J Clin Gastroenterol
. 2013
47
Suppl
S2
6
.14.
Pugh
RN
, Murray-Lyon
IM
, Dawson
JL
, Pietroni
MC
, Williams
R
. Transection of the oesophagus for bleeding oesophageal varices
. Br J Surg
. 1973
;60
(8
):646
–9
.15.
Johnson
PJ
, Berhane
S
, Kagebayashi
C
, Satomura
S
, Teng
M
, Reeves
HL
et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade
. J Clin Oncol
. 2015
;33
(6
):550
–8
.16.
Hiraoka
A
, Kumada
T
, Michitaka
K
, Toyoda
H
, Tada
T
, Ueki
H
et al. Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma
. J Gastroenterol Hepatol
. 2016
;31
(5
):1031
–6
.17.
Hiraoka
A
, Michitaka
K
, Kumada
T
, Izumi
N
, Kadoya
M
, Kokudo
N
et al. Validation and potential of albumin-bilirubin grade and prognostication in a nationwide survey of 46,681 hepatocellular carcinoma patients in Japan: the need for a more detailed evaluation of hepatic function
. Liver cancer
. 2017
;6
(4
):325
–36
.18.
Bruix
J
, Sherman
M
American Association for the Study of Liver Diseases
. Management of hepatocellular carcinoma: an update
. Hepatology
. 2005
;42
(5
):1208
–36
.19.
Di Martino
M
, Marin
D
, Guerrisi
A
, Baski
M
, Galati
F
, Rossi
M
et al. Intraindividual comparison of gadoxetate disodium-enhanced MR imaging and 64-section multidetector CT in the Detection of hepatocellular carcinoma in patients with cirrhosis
. Radiology
. 2010
;256
(3
):806
–16
.20.
Sano
K
, Ichikawa
T
, Motosugi
U
, Sou
H
, Muhi
AM
, Matsuda
M
et al. Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging
. Radiology
. 2011
;261
(3
):834
–44
.21.
The Liver Cancer Study Group of Japan
The general rules for the clinical and pathological study of primary liver cancer
Tokyo Kanehara
2015
. p. 26
.22.
Kanda
Y
. Investigation of the freely available easy-to-use software “EZR” for medical statistics
. Bone Marrow Transpl
. 2013
;48
(3
):452
–8
.23.
Saad
Y
, Said
M
, Idris
MO
, Rabee
A
, Zakaria
S
. Liver stiffness measurement by fibroscan predicts the presence and size of esophageal varices in egyptian patients with HCV related liver cirrhosis
. J Clin Diagn Res
. 2013
;7
(10
):2253
–7
.24.
Petta
S
, Sebastiani
G
, Bugianesi
E
, Viganò
M
, Wong
VW
, Berzigotti
A
et al. Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis
. J Hepatol
. 2018
;69
(4
):878
–85
.25.
Muñoz-Codoceo
C
, Amo
M
, Martín
A
, Martín-Arriscado Arroba
C
, Cuevas Del Campo
L
, Manzano
ML
et al. Diagnostic accuracy of liver and spleen stiffness measured by fibroscan® in the prediction of esophageal varices in HCV-related cirrhosis patients treated with oral antivirals
. Gastroenterol Hepatol
. 2021
;44
(4
):269
–76
.26.
Lisotti
A
, Azzaroli
F
, Buonfiglioli
F
, Montagnani
M
, Cecinato
P
, Turco
L
et al. Indocyanine green retention test as a noninvasive marker of portal hypertension and esophageal varices in compensated liver cirrhosis
. Hepatology
. 2014
;59
(2
):643
–50
.27.
Lisotti
A
, Azzaroli
F
, Cucchetti
A
, Buonfiglioli
F
, Cecinato
P
, Calvanese
C
et al. Relationship between indocyanine green retention test, decompensation and survival in patients with Child-Pugh A cirrhosis and portal hypertension
. Liver Int
. 2016
;36
(9
):1313
–21
.28.
Hiraoka
A
, Kumada
T
, Kudo
M
, Hirooka
M
, Tsuji
K
, Itobayashi
E
et al. Albumin-bilirubin (ALBI) grade as part of the evidence-based clinical practice guideline for HCC of the Japan society of hepatology: a comparison with the liver damage and child-pugh classifications
. Liver cancer
. 2017
;6
(3
):204
–15
.29.
Blendis
LM
, Orrego
H
, Crossley
IR
, Blake
JE
, Medline
A
, Isreal
Y
. The role of hepatocyte enlargement in hepatic pressure in cirrhotic and noncirrhotic alcoholic liver disease
. Hepatology
. 1982
;2
(5
):539
–46
.30.
Oshita
M
, Takei
Y
, Kawano
S
, Yoshihara
H
, Hijioka
T
, Fukui
H
et al. Roles of endothelin-1 and nitric oxide in the mechanism for ethanol-induced vasoconstriction in rat liver
. J Clin Invest
. 1993
;91
(4
):1337
–42
.31.
Hiraoka
A
, Nakai
M
, Hara
N
, Hanai
T
, Namisaki
T
, Miyaaki
H
et al. Clinical features of patients with chronic liver disease in Japan related to alcohol use: nationwide examination using alcohol use disorders identification test
. Hepatol Res
. 2023
;53
(1
):43
–50
.© 2023 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2023
You do not currently have access to this content.
